You are here

Takeda

These nine companies are working on coronavirus treatments or vaccines — here’s where things stand

Marketwatch

Sun, 03/8/20 - 11:26 pm

Gilead Sciences

Moderna Therapeutics

Vir Biotchnology

Takeda and Arcturus join hunt for coronavirus therapies

Pharmaforum

Thu, 03/5/20 - 10:50 am

drug development

Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes

Endpoints

Wed, 03/4/20 - 07:55 pm

Takeda Acquires Celiac-Focused PvP Biologics in Deal Worth $330 Million

BioSpace

Wed, 02/26/20 - 10:34 am

Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC

Pharmaceutical Business Review

Tue, 02/25/20 - 10:19 am

priority review

non-small cell lung cancer

Novimmune unit nabs Takeda milestone payment for hemophilia work

Fierce Biotech

Fri, 02/14/20 - 10:40 am

Light Chain Bioscience

Takeda invests in patient-centric data firm Seqster

Pharmaforum

Thu, 02/13/20 - 10:42 am

MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner

Endpoints

Thu, 02/6/20 - 11:50 am

natural killer cell therapy

Takeda Pharmaceutical Raises Its Profit Outlook

Motley Fool

Tue, 02/4/20 - 11:21 pm

Takeda puts Shire biologics plant with 200 employees on the block

Fierce Pharma

Fri, 01/31/20 - 11:00 am

drug manufacturing

Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor

BioSpace

Wed, 01/22/20 - 11:08 am

Charles River pens Takeda early-stage drugs deal

Fierce Biotech

Mon, 01/13/20 - 10:53 am

Charles River Laboratories

Takeda to Fund AI Projects at MIT as Part of New 3-Year Collaboration

Xconomy

Tue, 01/7/20 - 10:50 am

artificial intelligence

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Fierce Pharma

Thu, 12/19/19 - 11:32 pm

Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone

BioSpace

Thu, 12/19/19 - 12:56 pm

Turnstone Biologics

Takeda and Cerevance Team Up to Take on GI Diseases

BioSpace

Thu, 12/19/19 - 12:08 am

gastrointestinal disease

As NASH shifts again, the focus remains on Genfit’s big readout

EP Vantage

Wed, 12/18/19 - 10:53 am

Boehringer Ingelheim

Gilead Sciences

Intercept Pharma

ASH: Takeda details Ninlaro's miss in scrapped AL amyloidosis trial

Fierce Pharma

Mon, 12/9/19 - 09:59 am

Takeda's dengue vaccine efficacy slips between 12- and 18-month analyses

Fierce Pharma

Mon, 11/25/19 - 09:52 pm

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Pharmaforum

Mon, 11/25/19 - 09:49 am

clinical trials

ALK-positive non-small cell lung cancer

Pages